Orchestra BioMed logo

Close

  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial & Filings
    • IR Resources
  • Contact Us

Our Innovations

Pipeline

Advancing a multi-asset pipeline of high-impact therapeutic solutions

Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential for value creation using our partnership-enabled business model.

SWIPE TO SCROLL swipe to scroll
Pipeline Chart

Our flagship product candidates, BackBeat CNT and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:

  • Target mature therapeutic device markets with significant unmet needs
  • Provide high impact procedure-based solutions with rapid adoption potential
  • Offer strategic and financial benefits to a commercial partner and Orchestra BioMed

*Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for: 1The balloon dilatation of the stenotic portion (up to 26 mm length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter; 2The balloon dilation of the de novo stenotic portion (up to 26mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter; 3The balloon dilatation of the stenotic portion (up to 18 mm length) of an infrapopliteal artery (P-3 segment or distal, below the knee, with reference vessel diameter (RVD) 2.25 - 4.0 mm), for the purpose of improving lumen diameter.

Virtue® SAB is not approved for commercial use in the US

BackBeat CNT™ is not approved for commercial use in the US

Orchestra BioMed logo
  • Who We Are
    Our Approach
    Our People
    Careers
  • Our Innovations
    Pipeline
    Therapeutic Areas
    Virtue® SAB
    BackBeat CNT™
    FreeHold Retractors
  • Investor Relations
    Overview
    News & Events
    Stock Information
    Corporate Governance
    Financial & Filings
    IR Resources
  • Contact Us

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Disclaimer